Skip to main content

Table 2 Percent differences within metabolic syndrome and insulin resistance subgroups in LDL-C, total cholesterol, HDL-C and triglycerides

From: Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

  Abdominal Obesitya TG HDL-C SBP (DBP) FG HOMA-IR
  No Yes <150 mg/dL ≥150 mg/dL ≥40 mg/dL <40 mg/dL <130 (85) mmHg ≥130 (85) mmHg <100 mg/dL ≥100 mg/dL <2.72 2.72-4.81 >4.81
  n = 20-36 n = 177-196 n = 62-77 n = 142-155 n = 82-99 n = 119-135 n = 11-21 n = 194-205 n = 52-75 n = 144-165 n = 57-81 n = 68-78 (n = 69-79
LDL-C, mg/dL (95 % CI)              
 E/S20 - A10b −8.6 (−17.3, 0.1) −13.9 (−17.6, −0.3)* −15.8 (−21.7, −10.0)* −11.8 (−15.9, −7.7)* −14.3 (−19.3, −9.2)* −12.2 (−16.7, −7.8)* −17.8 (−31.8, −3.8)* −12.9 (−16.3, −9.4)* −9.5 (−15.4, −3.6)* −14.9 (−19.0, −10.9)* −11.1 (−16.7, −5.4)* −15.9 (−21.8, −10.0)* −12.3 (−18.2, −6.5)*
 E/S20 - A20b −9.1 (−17.8, −0.4)* −10.4 (−14.1, −6.8)* −12.0 (−17.7, −6.3)* −9.3 (−13.4, −5.2)* −9.1 (−14.1, −4.1)* −11.1 (−15.6, −6.6)* −9.8 (−21.8, 2.2) −10.3 (−13.8,-6.8)* −6.8 (−12.7, −0.9)* −11.9 (−16.0, −7.9)* −12.3 (−17.9, −6.7)* −10.3 (−16.2, −4.4)* −7.7 (−13.5, −1.8)*
 E/S40 - A40b 2.0 (−8.4, 12.4) −9.3 (−12.8, −5.8)* −9.8 (−16.0, −3.6)* −7.2 (−11.2,-3.2)* −5.90 (−11.3, −0.5)* −9.2 (−13.4, −4.9)* −2.4 (−13.5, 8.8) −8.5 (−12.0, −5.0)* −7.6 (−14.0,-1.1)* −8.0 (−11.9,-4.1)* −8.1 (−14.2, −2.0)* −8.9 (−14.5, −3.2)* −7.1 (−12.9, −1.4)*
TC, mg/dL (95 % CI)              
 E/S20 - A10b −4.8 (−11.2, 1.5) −7.7 (−10.3, −5.1)* −10.2 (−14.4, −5.9)* −5.8 (−8.8, −2.9)* −7.6 (−11.2, −3.9)* −7.0 (−10.2, −3.8)* −10.6 (−20.8, −0.5)* −7.0 (−9.5, −4.5)* −4.3 (−8.5, 0.0) −8.7 (−11.6, −5.7)* −6.1 (−10.2, −2.0)* −8.4 (−12.6, −4.1)* −7.1 (−11.4, −2.9)*
 E/S20 - A20b −4.8 (−11.0, 1.5) −5.5 (−8.1, −2.8)* −7.1 (−11.2, −3.0)* −4.4 (−7.4, −1.4)* −4.6 (−8.2,-1.0)* −6.0 (−9.2, −2.7)* −4.6 (−13.3, 4.2) −5.5 (−8.0, −2.9)* −2.8 (−7.1, 1.5) −6.6 (−9.6, −3.7)* −7.4 (−11.4, −3.3)* −4.8 (−9.1, −0.5)* −3.7 (−8.0, 0.6)
 E/S40 - A40b −3.0 (−10.6, 4.6) −4.8 (−7.3, −2.2)* −4.3 (−8.8, 0.2) −4.5 (−7.4, −1.6)* −3.1 (−7.0, 0.9) −5.3 (−8.4, −2.2)* −1.0 (−9.0, 7.0) −4.8 (−7.3, −2.2)* −4.9 (−9.6, −0.2)* −4.1 (−7.0, −1.3)* −5.8 (−10.2,-1.3)* −4.8 (−8.9, −0.6)* −2.6 (−6.8, 1.5)
HDL-C, mg/dL (95 % CI)              
 E/S20 - A10b 2.4 (−4.5, 9.3) 3.3 (0.4, 6.2)* 3.9 (−0.7, 8.5) 3.2 (0.0, 6.5) 1.3 (−2.6, 5.3) 5.0 (1.4, 8.5)* 9.8 (−1.3, 20.8) 3.0 (0.3, 5.7)* 3.2 (−1.4, 7.8) 3.4 (0.2, 6.6)* 4.2 (−0.2, 8.7) 4.1 (−0.5, 8.8) 1.4 (−3.2, 6.0)
 E/S20 -A20b −0.2 (−7.0, 6.7) 1.6 (−1.3, 4.5) 2.0 (−2.5, 6.5) 0.8 (−2.5, 4.0) 0.0 (−3.9, 3.9) 2.2 (−1.4, 5.7) 8.9 (−0.6, 18.4) 0.4 (−2.3, 3.2) 0.8 (−3.9, 5.4) 1.3 (−1.9, 4.5) 3.0 (−1.4, 7.4) −0.3 (−5.0, 4.4) 0.2 (−4.4, 4.9)
 E/S40 - A40b −2.8 (−11.0, 5.5) 4.7 (1.9, 7.5)* 5.0 (0.1, 9.9)* 3.6 (0.5, 6.7)* 4.3 (0.1, 8.6)* 3.7 (0.4, 7.1)* 9.1 (0.3, 17.9)* 3.5 (0.7, 6.2)* 4.8 (−0.3, 9.9) 3.2 (0.1, 6.3)* 5.6 (0.8, 10.5)* 4.9 (0.4, 9.4)* 1.1 (−3.5, 5.6)
TG, mg/dL (95 % CI)              
 E/S20 - A10b −7.4 (−20.3, 6.4) 0.1 (−4.7, 4.6) −0.9 (−9.0, 6.2) −1.5 (−6.8, 3.5) 1.8 (−5.2, 8.3) −3.1 (−9.1, 2.4) −2.7 (−20.8, 11.1) −0.8 (−5.4, 3.6) −0.3 (−7.9, 7.7) −1.3 (−6.8, 3.9) −3.9 (−11.7, 3.9) 1.4 (−6.1, 8.8) −0.3 (−8.1, 6.9)
 E/S20 - A20b −0.8 (−12.9, 11.5) 3.5 (−1.3, 8.2) 7.3 (−0.2, 14.8) 0.3 (−5.0, 5.7) 4.3 (−2.3, 11.1) 1.7 (−4.1, 7.3) 2.1 (−11.1, 16.2) 2.9 (−1.7, 7.5) 2.4 (−4.7, 10.8) 2.7 (−2.5, 8.3) −0.1 (−8.0, 8.2) 4.2 (−3.5, 12.2) 3.6 (−4.0, 10.5)
 E/S40 - A40b −0.3 (−19.6, 15.4) −0.4 (−4.9, 4.1) 2.2 (−6.6, 10.9) −1.4 (−6.4, 3.5) −1.6 (−8.8, 5.1) 0.4 (−5.3, 5.8) −2.7 (−18.5, 11.5) −0.1 (−4.7, 4.5) −6.1 (−13.9, 2.6) 1.9 (−3.4, 6.9) −4.0 (−12.7, 4.9) −1.2 (−8.2, 5.7) 4.8 (−3.3, 12.3)
  1. A10/20/40 = atorvastatin 10/20/40 mg; E = ezetimibe 10 mg; FG = fasting glucose; HDL-C = high density lipoprotein cholesterol; HOMA-IR = Homeostasis Model Assessment of Insulin Resistance; LDL-C = low density lipoprotein cholesterol, n = number of patients in subgroup (some numbers vary slightly between parameters), S20/40 = simvastatin 20/40 mg; SBP (DBP) = systolic blood pressure (diastolic blood pressure); SD = standard deviation; TG = triglycerides
  2. *Confidence intervals of difference parameters do not contain 0 aabdominal obesity = waist circumference ≥40 inches for males or ≥35 inches for females bbetween-treatment differences (E+S minus A) based on ANOVA model with terms for subgroup (baseline abdominal obesity, TG, HDL-C, blood pressure, fasting glucose, and HOMA-IR, based on subgroup being analyzed), baseline stratum, treatment group, and the interaction of treatment group and subgroup Values in parentheses = 95% confidence intervals